Strategic interventions in clinical randomized trials for metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity in the pediatric population: a systematic review with meta-analysis and bibliometric analysis Authors: Isabel Omaña-Guzmán, Marisol Rosas-Diaz, Yoscelina Estrella Martínez-López, L Monserrat Perez-Navarro, Alvaro Diaz-Badillo, Anthony Alanis, Alejandra Bustamante, Octelina Castillo-Ruiz, Noemi del Toro-Cisneros, Diego Armando Esquivel-Hernandez, Gloria Garcia-Villalobos, Nayely Garibay-Nieto, Esperanza Milagros Garcia-Oropesa, Juan Carlos Hernandez-Martinez, Elena Beatriz Lopez-Sosa, Carlos Maldonado, David Martinez, Joshua Membreno, Oscar Omar Moctezuma-Chavez, Claudia X Munguia-Cisneros, Edna J Nava-González, Adriana L Perales-Torres, Adolfo Pérez-García, Hector Rivera-Marrero, Alisha Valdez, Alfonso Alejandro Vázquez-Chávez, Carlos Ramirez-Pfeiffer, Kathleen V Carter, Beatriz Tapia, Leonel Vela, Juan Carlos Lopez-Alvarenga Published: 2024 ABSTRACT AbstractBackgroundMetabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is a prevalent hepatic condition linked to metabolic alterations. It gradually causes liver damage and potentially progresses to cirrhosis. Despite its significance, research, especially in the pediatric population, is limited, leading to contradictory findings in diagnosis and treatment. This meta-analysis aims to synthesize existing literature on therapeutic interventions for MASLD in children and adolescents.MethodsA comprehensive search of randomized controlled clinical trials yielded 634 entries from PubMed, Scopus, and Web of Science up to 2023. Interventions included medications, behavioral modifications, dietary changes, probiotics, supplements, surgical procedures, or combinations. The analysis focused on studies with treatment duration of at least 3 months, employing a random-effects REML meta-analysis model. Treatment effects on anthropometric measurements and biochemical components were examined and adjusted for heterogeneity factors analysis. A bibliometric analysis for insights into research contributors was performed.ResultsThe systematic review incorporated 31 clinical trials, with 24 meeting criteria for meta-analysis. These comprised 3 medication studies, 20 with supplements, 4 focusing on lifestyle, and 4 centered on diets. Significant overall treatment effects were observed for ALT, AST, BMI, and HOMA-IR mainly by supplements and lifestyle. Meta-regression identified age, BMI changes, and treatment duration as factors modifying ALT concentrations. Bibliometric analysis involving 31 linked studies highlighted contributions from 13 countries, with the USA, Spain, and Chile being the most influential.ConclusionsWe conclude that supplementation and lifestyle changes can effectively impact ALT and AST levels, which can help address liver issues in obese children. However, the evaluation of risk bias, the high heterogeneity, and the bibliometric analysis emphasize the need for more high-quality studies and broader inclusion of diverse child populations to provide better therapeutic recommendations.Trial registrationPROSPERO, CRD42023393952. Registered on January 25, 2023.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12916-024-03744-x.Keywords: MASLD (metabolic dysfunction-associated steatotic liver disease), Pediatric NAFLD, Therapeutic interventions, Randomized controlled trials, Meta-analysis, Liver enzymes Background The metabolic dysfunction-associated steatotic liver disease (MASLD), formerly named non-alcoholic fatty liver disease (NAFLD), is a prevalent hepatic condition associated with metabolic disruptions leading to gradual liver tissue damage (steatosis and steatohepatitis) and eventual progression to cirrhosis or subsequent hepatocellular carcinoma [1]. In the pediatric population, MASLD is one of the leading causes of chronic liver disease, and its global prevalence has been estimated between 7 and 35%, depending on the diagnosis method, setting population, and geographical region [2]. The prevalence is higher in children and adolescents with obesity (about 34.2%) [2] and is expected to increase alongside the global obesity pandemic. The causes of MASLD include hormonal, genetic, or lifestyle-associated factors, alongside cardiometabolic risk factors (excess of adipose tissue, high lipid profile levels, insulin resistance, or glucose intolerance). Additionally, studies have identified genetic mutations affecting hepatic fat metabolism that increase the risk of MASLD (i.e., PNPLA3 1148 m and TM6SF2 E167K) [3]. Despite its clinical consequences, pediatric MASLD is commonly underdiagnosed due to the lack of accurate, validated, and accessible diagnostic tools in clinical settings. No effective treatments are currently available for MASLD in adult and pediatric populations [4]. The focus of management revolves around lifestyle modifications (diet and exercise), food supplements (e.g., vitamin E, probiotics, omega-3 fatty acids), and bariatric surgery [5]. Dietary improvements and increased physical activity are primary treatments for pediatric MASLD due to its strong association with excess weight gain and obesity. Lifestyle intervention studies vary significantly in design, duration, inclusion criteria, outcomes, and approaches, and interpreting results is challenging [6]. Aims Considering the clinical relevance of MASLD in the pediatric population and the scarce evidence about effective interventions for this condition, the primary objective of this study was to identify and synthesize studies of therapeutic interventions for MASLD in children and to perform a meta-analysis to calculate the effect of different therapeutic strategies targeted to improve biochemical, anthropometric, and histological parameters related to MASLD and its progression stages. This study includes the most significant number of analyzed studies and synthesizes the latest evidence to offer a robust and nuanced understanding of the efficacy and safety of various interventions. Additionally, a bibliometric analysis [7, 8] was conducted to analyze the research landscape, identify gaps, and elucidate the impact and network of researchers within this field. This exploration aimed to identify evolving themes and treatments, offering insights into future trajectories for research. Methods This systematic review followed the PRISMA (Preferred Reporting Items for Systemic Reviews and Meta-Analyses) guidelines for systematic reviews and meta-analyses [9]. The protocol for this study was registered in PROSPERO on January 25, 2023, and assigned the registry number CRD42023393952 [10]. The research question was developed using the PICO (patients, intervention, comparison, outcomes) framework as follows: Participants/population We included randomized controlled clinical trials (RCTs) involving pediatric patients of all ages and both sexes diagnosed with metabolic-associated fatty liver disease (MAFLD), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), fatty liver, and liver steatosis. Analysis for sex comparison was not possible as most papers did not analyze these contrasts. Intervention Only studies that addressed treatments to improve MASDL in children and adolescents were included. Therapeutic interventions included alternative medicine, pharmacological approaches, nutritional interventions, behavioral interventions, and surgical procedures. Comparisons The systematic review included RCTs comparing treatments or strategies, including but not limited to placebo, medication, behavioral modifications, dietary changes, probiotics, supplements, and surgical procedures. To mitigate the placebo effect, studies with a minimum treatment duration of 3 months were eligible for inclusion in the meta-analyses. Outcomes Data extraction focused on assessing the size of treatment effects on various parameters, including hepatic enzymes (alanine aminotransferase (ALT), aspartate transaminase (AST), gamma-glutamyl transferase (GGT), anthropometric measurements (BMI, body fat percentage, waist circumference), biochemical components (HDL-cholesterol (HDL-C), triglycerides (TG), glucose, LDL-Cholesterol (LDL-C)), and other cardiometabolic risk factors (insulin resistance measurements, total cholesterol (TC), uric acid). Search strategies The search strategies employed Ovid MEDLINE, Cochrane CENTRAL, and Web of Science databases to retrieve literature published up to 2023, explicitly targeting randomized controlled clinical trials. The search terms utilized subject headings and keywords related to NAFLD, NASH, fatty liver, and liver steatosis. Pediatric population descriptors were adapted from LeClercq et al. [11]. The Cochrane Highly Sensitive Search Strategy was incorporated to identify randomized trials in MEDLINE, Ovid Format (2008 revision). No restrictions regarding date, language, or filters were applied to the search. The search strategy initially developed for Ovid MEDLINE was subsequently adapted for use in Cochrane CENTRAL and Web of Science. The Supplementary Literature Research Strategy (Additional File 13: Supplementary file 13) provides detailed information on the used literature search. To expand our literature search, we proactively contacted authors from obesity and diabetes meetings with abstracts, aiming to include any additional studies and gray literature in our analysis. Eligibility criteria for outcomes of MASLD The systematic review considered RCTs that evaluated the effect of therapeutic interventions in the pediatric population (18 years or younger) diagnosed with MASLD, NAFLD, NASH, fatty liver, and liver steatosis diagnosed by biochemical, image tools, or liver biopsy. The range of interventions encompassed pharmaceutical, behavioral, surgical, nutritional, and alternative approaches. Our criteria did not impose limitations based on language, sex, or blinding status. Exclusions comprised retrospective and observational studies, commentaries, expert opinions, editorials, and other non-original studies. Studies in children with diabetes diagnoses were excluded. For the meta-analysis, interventions with less than 12 weeks of treatment were excluded, while those falling below this threshold were included in the qualitative systematic review. Studies selection Study entrees were initially retrieved from three databases: Ovid Medline (n = 448), Cochrane CENTRAL (n = 429), and Web of Science (n = 596). Data extraction process Post-search, all identified citations were compiled and imported into EndNote 20 (Clarivate Analytics), with duplicates removed. A pilot title/abstract screening involving 1,106 citations was executed using Rayyan [12], ensuring a minimum 75% agreement between reviewers before the formal review commenced. Subsequently, abstracts and titles were screened independently by 27 reviewers against the inclusion criteria using Rayyan, and at least two independent reviewers screened each paper. A data extraction adapted from the Cochrane Collaboration was used for data collection. Detailed information was extracted, such as type of intervention, age of participants, treatment duration, year of study development, country of residence, eligibility criteria, sample size, definition of intervention and control groups, treatment blinding, and effect sizes (Cohen’s d). Discrepancies were resolved through re-analysis by groups of four investigators. The authors were contacted for additional information when necessary. The main outcomes focused on ALT, AST, GGT, TG, LDL-C, HDL, TC, glucose, HOMA-IR, BMI reduction, waist circumference, body fat percentage, and biochemical metabolism parameters considered as associated outcomes. Quality and risk of bias assessment The planned quality assessment involved the Jadad scale [13] and the risk of bias using the description of randomization, blinding withdrawals, and dropouts in the studies. Both the study scanning and selection, along with data extraction using the Cochrane tool and quality assessment via the Jadad scale, were carried out in a paired manner by investigators to minimize bias. For the systematic review, studies with a Jadad score greater or equal to 3 were included, while those with a score > 3 were included for the meta-analysis. We evaluated the risk of bias (RoB) that reflects the methodological quality of the included studies using the criteria published by Higgins et al. [14] that include the following domains assessed: (1) random sequence generation, (2) allocation concealment, (3) blinding participants and personnel (performance bias), (4) blinding of outcome assessment (detection bias), (5) incomplete outcome data (attrition bias), (6) selective reporting (reporting bias), and (7) other bias. The evaluation was done by groups of three researchers to obtain agreement with the scores and was reviewed by another independent team. This assessment helps to determine the reliability and validity of the included studies in a systematic review or meta-analysis, ensuring that the conclusions drawn are based on robust and credible evidence with graphics generated for easy interpretation of the results (Fig. 2). Risk of bias assessment. Low risk of bias (green) indicates that the study has a low likelihood of bias affecting the results. Unclear risk of bias (yellow) indicates insufficient information to determine the risk of bias. A high risk of bias (red) indicates that there is a high likelihood that bias could have influenced the study’s results. The right column shows treatment’s groups. Using multiple combinations of interventions increases the complexity and does not allow blindness implementation Statistical analysis Sample size, means, and standard deviations were extracted from the included studies’ data for the statistical analysis. Cohen’s d size of effects with 95% confidence intervals (95% CI) was computed to summarize contrasts between intervention types and overall interventions. All models were analyzed using restricted maximum likelihood (REML) random effects models due to the high variation between the effect sizes. Heterogeneity was assessed using tau2 and I2 statistics. The tau2 measures the between-study variance in a random-effects meta-analysis to quantify the variability in effect sizes attributable to heterogeneity rather than chance. The tau2 specifies the value of the between-study variance parameter or the random effects in meta-regression. Meanwhile, the I2 statistic describes the proportion of total variation in study estimates due to heterogeneity rather than chance [15]. In order to address bias in the randomization process such as significant differences in basal weight between treatments in some studies, we adjusted the meta-analysis using mean baseline values [16] and effect sizes, assessed with Hedges’ g [17], to correct for small sample sizes. We have displayed unadjusted and adjusted results in forest plots for ALT, AST, BMI, and HOMA-IR. These results indicate similar point effect estimates with small standard errors. In addition, we performed meta-regressions to examine potential sources of heterogeneity, considering mean age, mean BMI, gross domestic product (GDP) by country, sex distribution, and study duration as contributing variables. The Egger test was conducted on the slopes in the weighted regression of the effect size to evaluate the presence of publication bias. Sensitivity analysis The sensitivity analysis was performed with a one-study-removed to evaluate the stability and reliability of the meta-analysis results. This strategy helped to detect any single study that significantly altered the pooled effect size (Additional File 14: Supplementary file 14). Statistical analyses were performed with Stata 18.0 (StataCorp, College Station TX). Bibliometric analysis A bibliometric analysis of the papers in this systematic review was conducted to identify research networks investigating therapeutic interventions for MASLD in children and trends and co-occurrence of themes in the literature. The bibliometric analysis was performed with the VOSviewer release 1.6.19 [18]. The analysis sought to identify relationships between investigators, so researchers with at least two published studies were included. The methodology incorporated performance measurement (research impact), network analysis, and scientific mapping to conduct a systematic evaluation of citation patterns, publication trends, and author collaborations [19–21]. Results A total of 1473 studies were initially retrieved from three databases: Ovid Medline (n = 448), Cochrane CENTRAL (n = 429), and Web of Science (n = 596). After removing duplicates and applying eligibility criteria, 1386 studies were excluded, leading to the final inclusion of 87 studies. Figure 1 presents a PRISMA flow diagram detailing the study retrieval and screening process. PRISMA 2009 flow diagram for study selection These 87 studies underwent data extraction using the Cochrane tool and were subsequently assessed for quality using the Jadad scale. Following a thorough third-round screening based on inclusion criteria, 31 studies were ultimately selected for the systematic review, with 24 chosen for the subsequent meta-analysis (Fig. 1). Characteristics of included studies In the systematic review, 31 controlled clinical trials involving overweight and obese children subjected to various weight-loss interventions were considered. The distribution of interventions was as follows: pharmaceutical (3 studies), supplements (21 studies), lifestyle modifications (2 studies), diet (6 studies), supplement plus lifestyle (2 studies), and diet plus supplement (1 study). An aggregate analysis of the studies is described in Table 1. Three studies evaluated at least two different types of interventions [22–24]. Table 1Characteristics of the analyzed interventions (n = 31). Mean age was adjusted by study's group sample size. *For the cross-over design, the mean age was not providedType of interventionN (31)Control group mean ageIntervention group mean ageReferences A. Medication312.613.1 [6, 22, 23]B. Supplementation20B1. Only supplements1712.011.7 [25–41]B2. Supplements + Lifestyle212.812.3 [24, 42]B3. Supplements + Diet14 to 14 years* [43]C. Lifestyle214.315.0 [44, 45]D. Diet613.613.7 [46–51] Characteristics of the analyzed interventions (n = 31). Mean age was adjusted by study's group sample size. *For the cross-over design, the mean age was not provided The age differences among strategies for intervention show minor variability. The average age for medications was 12.6 years for the control group and 13.1 years for the intervention group. In contrast, dietary-only interventions exhibited comparable ages between groups (13.6 for controls and 13.7 for interventions). Supplement-only studies included younger individuals, with mean ages of around 12.0 years for the control group and 11.7 years for the intervention group. Lifestyle interventions predominantly involved older children, with mean ages of 14.3 for the control group and 15.0 for the intervention group. These age trends could suggest intervention strategies tailored for different age groups or developmental stages. Participant countries The geographical distribution of participant cities revealed Italy with the highest frequency of studies (n = 11), followed by the USA (n = 7) and Iran (n = 5). Other contributing countries included Turkey, Brazil, Egypt, China, Hong Kong, India, South Korea, Poland, Spain, Sri Lanka, and Thailand. Risk of bias and quality assessment For the studies included in the meta-analysis, the median total Jadad score was 5 (IQR: 4–5). According to the evaluation, 95.8% (n = 23) of the studies reported an adequate blinding method, and 91.6% (n = 22) used an adequate randomized method. Regarding the risk of bias, we found that most of the included studies had a low overall risk of bias, as shown in Fig. 2. Because of the nature of the intervention, the studies with diet were not blinded to participants or health personnel. Synthesis of results This systematic review and meta-analysis included data from 2066 participants across randomized controlled studies targeting children with MASLD. The median of participant children per study was 60 (Q1 = 44, Q3 = 75). The predominant interventions frequently employed, either individually or in combination, were supplements, diet, lifestyle modifications, and medications (Table 1). The characteristics of the included studies are described in Table 2. Table 2Descriptive analysis of the systematic reviewAuthor, year, countryParticipants(inclusion criteria)Sample sizeIntervention implemented (INT)/versus placebo (PLB) or control (CTL)Type of interventionTreatment duration (months)ObjectiveSignificant differences between groups and variables1) Nobili V, [25] 2006,Italy1. Children (aged 3–18 years)2. Persistently elevated serum aminotransferase levels3. Diffusely echogenic liver in imaging studies suggestive of fatty liver4.No use of drugs known to induce steatosisTotal: 90INT: 45PLB: 45INT: vitamin E (600 IU/day) and vitamin C (500 mg/day) + dietPLB: nutritional counseling + placeboSupplement12To compare the effect of a nutritional programed alone or combined with alpha-tocopherol and ascorbic acid on alanine aminotransferase (ALT) levels, and insulin resistance (IR) in biopsy-proven NAFLD childrenYes: Among subjects who lost excessive weight, ALT and body weight percentage changes were significantly related. HOMA-IR and ALT significantly decreased in both groupsNo: The addition of antioxidant vitamins E and C to a healthier diet and daily regular physical activity seems to have no significant effect on reducing circulating ALT levels, liver brightness, and IR in NAFLD children2) Nobili V, [26] 2008,Italy1. Persistently elevated serum aminotransferase levels2. Diffusely echogenic liver on imaging studies suggestive of fatty liver2. Biopsy consistent with the diagnosis of NAFLDTotal: 53INT: 25PLB: 28INT: vitamin E (600 IU/day) and vitamin C (500 mg/day) + lifestyle interventionPLB: capsules of placebo + lifestyle interventionSupplement24To determine the efficacy of lifestyle intervention with or without antioxidant therapy in pediatric NAFLDYes: Lifestyle intervention with diet and increased physical activity induces weight loss and significantly improves liver histology and laboratory abnormalities in pediatric NAFLDNo: Alpha-tocopherol plus ascorbic acid does not seem to increase the efficacy of lifestyle intervention alone3) Wang CL, [42] 2008,China1. Children 10–17 years2. BMI > 95th percentile for age and sex3. NASH (ultrasound)4. ALT > 1.5 times over the upper normal limitTotal: 76INT1: 19INT2: 19CTL: 38INT 1: lifestyle intervention (summer camp)INT 2: vitamin E (100 mg/day)CTL: without any intervention1. Lifestyle2. Supplement1To investigate the short-term effect of a lifestyle intervention on liver biochemistry and fasting insulin levels and compare it with that of vitamin E therapy in obese children with NAFLDYes: Both a short-term lifestyle and vitamin E therapy were effective in NAFLD. Compared with vitamin E, lifestyle intervention is more effective (triglyceride, cholesterol, and insulin resistance)4) Akcam M, [22] 2011,Turkey1. Children 9–17 years2. Liver steatosis and obesityTotal: 67INT1: 22INT2: 22CTL: 23INT1: metformin (850 mg/day)INT2: Vit E (400 IU/day)CTL: diet, exercise, and behavioral therapy1. Medication2. Supplement6To evaluate the therapeutic effect of vitamin E and metformin in a population of obese adolescents with NAFLDYes: Metformin treatment is more effective than dietary advice and vitamin E treatment in reducing insulin resistance and ameliorating metabolic parameters such as fasting insulin and lipid levels in obese adolescents with NAFLD5) Lavine J, [23] 2011,United States1. Patients aged 8 to 17 years with NAFLD (defined by liver biopsy demonstrating > or equal 5% fat content)2. Persistently elevated levels of ALT were eligibleTotal: 173INT1: 58INT2: 57PLB: 58INT1: vitamin E (400 mg/day)INT2: metformin (500 mg/day)PLB: identical placebo1. Supplement2. Medication24To evaluate whether reduction in ALT defined as 50% or less of the baseline level or 40 U/L or less at visits every 12 weeks from 48 to 96 weeks of treatment. Improvements in histological features of NAFLD and resolution of NASH were secondary outcome measuresYes: The mean change in hepatocellular ballooning scores at 96 weeks was significant with vitamin E and metformin compared to placeboNo: Neither vitamin E nor metformin was superior to placebo in attaining the primary outcome of sustained reduction in ALT level in patients with pediatric NAFLD6) Nobili V, [27] 2011Roma1. Persistently elevated serum alanine transaminase (ALT ≥ 40 U/l)2. Diffusely hyperechogenic liver at ultrasonography3. Liver biopsy consistent with NAFLDTotal: 60INT1: 20INT2: 20CTL: 20INT1: DHA (250 mg/day)INT2: DHA (500 mg/day)CTL: linoleic acid (290 mg/day) supplied with germ oilSupplement6To investigate whether dietary supplementation with docosahexaenoic acid (DHA) decreases liver fat content in children with non-alcoholic fatty liver disease (NAFLD)Yes: DHA supplementation for 6 months reduced liver fat content and increased insulin sensitivity in children with NAFLD. However, 250 mg/day of DHA was as effective as 500 mg/day in obtaining these outcomesNo: There was no effect on alanine transaminase and body mass index7) Nobili V, [28] 2013,Italy1) Age < 18 years2) Persistently elevated serum alanine transaminase (ALT 40 U/L)3) Diffusely hyperechogenic liver at ultrasonography4) Liver biopsy consistent with NAFLDTotal: 60INT1: 20INT2: 20PLB: 20INT1: DHA (250 mg/day)INT2: DHA (500 mg/day)CTL: linoleic acid (290 mg/day) supplied with germ oilSupplement24This study aimed to determine whether dietary supplementation with docosahexaenoic acid (DHA) can decrease liver fat content in children with NAFLDYes: DHA supplementation improved liver steatosis in children with NAFLD. Doses of 250 mg/day and 500 mg/day of DHA appear equally effective in reducing liver fat contentTriglycerides were lower in the DHA groups than in the placebo group at any time, and ALT was lower in these groups from month 12 onwards. HOMA was lower in the DHA 250 mg group vs. placebo at months 6 and 128) Ghergherehchi R, [29] 2012,Iran1. Children with BMI higher than 97th percentile for age and sex2. ALT, AST levels at least 1.5 times more than the upper limit of normality (5–40 IU/L)3. Signs of hepatic steatosis in ultrasonographyTotal: 33INT: 17PLB: 16INT: vitamin E (400 mg/day) + lifestylePLB: placebo + lifestyleSupplement6The purpose of this study was to investigate the effects of administering vitamin E for six months on the serum levels of hepatic enzymes and liver lipid contentYes: In 6 months of therapy, there was a significant change in body mass index, serum aminotransferases, triglycerides, total cholesterol, and low-density lipoprotein-cholesterol levels in both groupsNo. ALT decreased to normal levels in 8 of 17 patients (47.05%) in the lifestyle and vitamin E group and 7 of 16 patients (43.75%) in the lifestyle and placebo group. Similarly, the improvement in the grade of steatosis on ultrasonography after intervention was the same in both groups9) Jin Rl, [51] 2014,USA1) Self-identification as Hispanic2) Ages 11–18 years; BMI ≥ 85th percentile for age and gender3) Average self-reported consumption of at least 3 servings of sweet beverages (equivalent to 24 fl oz) per dayTotal: 21INT: 12CLT: 9INT: 3 servings (8 fl oz bottles) of study-provided beverages daily (33 g of glucose per serving)CLT: 3 servings (8 fl oz bottles) of study-provided beverages each day (33 g of fructose per serving)Diet1To evaluate whether hepatic steatosis and associated cardiovascular risk factors would be improved after 4 weeks of substitution of usual high fructose-containing beverages with study-provided glucose-only beveragesNo: there was no significant change in hepatic fat or body weight in either groupYes: In the glucose beverage group there was significantly improved adipose insulin sensitivity, high sensitivity C-reactive protein (hs-CRP), and low-density lipoprotein (LDL) oxidation10) Alisi A, [30] 2014,Italy1.BMI > 85th percentile2. Biopsy-proven NAFLDTotal: 44INT: 22PLB: 22INT: VSL#3 (sachets) + lifestyle interventionPLB: placebo sachets + lifestyle interventionSupplement4To assess the effect of VSL#3 supplementation on fatty liverYes: Supplementation with VSL#3 significantly improves fatty liver and BMI in children with NAFLDNo: No between-group differences were detected in triglycerides, HOMA and ALT11) Janczyk W, [31] 2015,Poland1. Age > 5 < 19 years2. Overweight or obesity3. ALT activity ≥ 1.3 times the upper limit of normal4. Presence of hyperechogenic liver on ultrasound or5. Liver histology consistent with NAFLD/nonalcoholic steatohepatitisTotal: 64INT: 30PLB: 34INT: omega-3 fatty acids, DHA and EPA (450–1300 mg/day)PLB: omega-6 sunflower oilSupplement6To evaluate the efficacy and safety of omega-3 fatty acid supplementation in children with nonalcoholic fatty liver disease (NAFLD)Yes: Patients in the omega-3 group had lower levels of aspartate aminotransferase and gamma-glutamyl transpeptidase, and significantly higher levels of adiponectinNo: Omega-3 fatty acid supplementation did not increase the number of patients with decreased ALT levels, and it did not affect liver steatosis on ultrasound12) Miccheli A, [32] 2015,Italy1. BMI > 85th percentile2. Biopsy-proven NAFLDTotal: 44INT: 22PLB:22INT: VSL#3 (1 sachet/day if the subject’s age was < 10 years, 2 sachets/day in children aged ≥ 10 years)PLB: placebo (1 sachet/day if the subject’s age was < 10 years, 2 sachets/day in children aged ≥ 10 years)Supplement4To identify urinary metabolic profiles, characterizing the effect of VSL#3 treatment on obese NAFLD children undergoing a lifestyle interventionYes: Supplementation with VSL#3 significantly improved fatty liver and BMI and provided differentially expressed urinary metabolites ('biomarkers') in children with NAFLD, as compared with the placebo group13) Pacifico L, [33] 2015,Italy1. Age < 18 years2. BMI > 85th percentile according to age- and gender3. Persistently elevated ALT levels4. NAFLD diagnosis by MRI and liver biopsy consistent with NAFLDTotal: 51INT. 25PLB: 26INT: DHA (250 mg/day)PLB: linoleic acid (290 mg/day)Supplement6To analyze whether 6-month treatment with DHA improves hepatic fat. Secondary: Waist circumference, ALT, triglycerides, insulin, hepatic fat fraction, visceral adipose tissue, epicardial fatYes: DHA supplementation decreases liver and visceral fat and ameliorates metabolic abnormalities (ALT, triglycerides, BMI, insulin sensitivity) in children with NAFLDNo: There were no significant between-group changes for LV function14) Della Corte C, [34] 2016,Italy1. Age 4–16 years2. Liver biopsy result consistent with a diagnosis of NAFLD/NASH3. Decreased serum vitamin D levels (< 20 ng/ml)4. ALT levels < 10 upper limit of normal5. No laboratory and/or clinical signs of liver decompensationTotal: 41INT:18PLB:23INT: DHA (500 mg/day) + vitamin D (800 IU/day)PLB: identical capsules (placebo)Supplement12To test the effect of daily DHA (500 mg) plus vitamin D (800 IU) treatment, in obese children with biopsy-proven NAFLD and vitamin D deficiency, in a randomized, double-blind placebo-controlled trialYes: DHA plus vitamin D treatment reduced the NAFLD Activity Score (NAS), in the treatment group (5.4 v1.92; p < 0.001 for baseline versus end of study). The triglycerides (174.5 vs. 102.15 mg/dl), ALT (40.25 vs. 24.5 UI/l) and HOMA-IR (4.59 vs. 3.42) were all decreased with treatmentNo: There was no change in fibrosis score15) Famouri F, [35] 2017,IranChildren 5–16 years with NAFLDTotal: 40INT:20PLB: 20INT: silymarin tablets (5 mg/kg/d, divided 3 doses with meal) + lifestylePLB: lifestyleSupplement3To investigate about this herbal drug on recovery of liver function tests and sonographic changesYes: Silymarin can improve fatty infiltration of liver and liver function in children and adolescents. ALT, AST, and TG were improved significantlyNo: LDL and HDL did not change during intervention in case group16) Famouri F, [36] 2017,Iran1. Children 10–18 years2. BMI ≥ 85th percentile3. Sonographic findings of NAFLDTotal: 64INT: 32PLB: 32INT: Prokid -Lactobacillus and Bifidobacterium (1 capsule/day)CTL: placebo capsuleSupplement3To evaluate the effects of some probiotics on sonographic and biochemical NAFLDYes: Supplementation with probiotic can be effective in improving pediatric NAFL. ALT, AST, cholesterol, HDL, TG, and waist circumference decreasedAfter the trial, compared with the placebo group, the frequency of normal liver ultrasonography was significantly higher, and the frequency of high-grade fatty liver was significantly lower than the placebo group (p < 0.05)17) De Lira CT, [44] 2017,Brazil1. Age 13–18 years with good general health2. BMI > 95th percentile according to the Centers for Disease Control (CDC)3. Tanner stage 3 to 4Total: 84INT1: 26INT2: 25CTL: 33INT1: high-intensity training (HIT) + nutritional, psychological and clinical counseling. INT2: low-intensity training (LIT) + nutritional, psychological and clinical counselingCTL: adolescents with lower intrinsic motivationLifestyle3To evaluate the effects of low versus high-intensity aerobic training on biomarkers related to NAFLD in adolescents with obesityYes: A significant improvement in lipid profile, ALT, AST, BMI, and fat mass was observed, irrespective of the intensity of aerobic training18) Schwimmer JB, [50] 2018,USA1. Adolescent boys aged 11 to 16 years2. Clinical-pathological diagnosis of NAFLD and current evidence of active diseaseTotal: 40INT: 20CTL: 20INT: low sugar dietCTL: usual dietDiet2To test the hypothesis that free sugar restriction would reduce hepatic fat content in children with NAFLDYes: Significant improvement in hepatic steatosis. ALT and total cholesterol levels improvedNo: There were no changes in glucose, insulin, and insulin resistance19) Chan DFY [45], 2018,Hong Kong1. Post-pubertal adolescents aged 14-–8 years2. Primary obesity (BMI ≥ Pc 95th of a local reference)Total: 52INT: 26 [20]CTL: 26 [22]INT phase I (INT PI): dietitian-led lifestyle modification intervention (D-MLP)Maintenancephase II (INT MPII): bimonthly visits for dietary advice (P-CON)CTL: usual clinical routine pediatric consultationsLifestyle16To evaluate the efficacy of a dietitian-led lifestyle modification programed (D-LMP) to reduce NAFLD in obese adolescentsYes: A dietitian-led lifestyle modification intervention reduced intra-hepatic triglyceride content (IHTC), BMI z-score and body fat in obese Chinese adolescents with NAFLD20) Nobili V, [37] 2019,Italy1. Children 4–16 years with liver steatosis (with biopsy)2. ALT levels < 10 upper limit of normal3. Without signs of liver decompensationTotal: 70INT: 35PLB: 35INT: hydroxytyrosol (HXT) (oral dose of 7.5 mg + 10 mg of vitamin E)PLB: capsules of placeboSupplement4To test the potential efficacy, assessed by improvement of oxidative stress parameters and liver ultrasound, and tolerability of a mixture of vitamin E and HXT in children and adolescents with biopsy proven NAFLDYes: The treatment improved the main oxidative stress parameters (carbonylated proteins (PCOs), S-nitrosylated proteins (PSNOs) and advanced glycation end products (AGEs)), insulin resistance (TG, fasting insulin and HOMA-IR), and steatosis in children with NAFLDNo: Anthropometric parameters remained almost unchanged in both groups (Placebo and Treatment arms)21) Goyal P, [24] 2019,India1. Child (5–18 years) with obesity using WHO standard reference and without alcohol intakeTotal: 106INT1:26INT2:27INT3:26PLB:27INT1: probiotics capsules VSL#3 + LifestyleINT2: probiotics capsules VSL#3INT3: lifestylePLB: placebo capsules (corn flour)Supplement + Lifestyle4To evaluate the potential of probiotic VSL#3 and Lifestyle modification in obese pediatrics with NAFLDYes: Probiotic VLS#3 and lifestyle intervention are effective for managing NAFLD in obese child but VSL#3 plus lifestyle intervention significantly the most pronounced therapy for reducing fatty liver grades and biochemical parameters (AST, ALT, GGT, LDL-c, HSCRP, cholesterol, TG, uric acid, FBG) and increase in HDL-c22) Negri R, [43] 2020,Italy1.Children 4–14 years2. BMI > 85th percentile2. Liver steatosis by USTotal: 52(T1) INT 34; PLB 27(T2) INT 26; PLB 26Cross-over trial designINT: calorie-restricted regimen (CRC) + lycopene-enriched tomato juice supplementation together with basil and oregano extract in extra virgin olive oilPLB: calorie-restricted regimenDiet + Supplement4To evaluate the effect of lycopene-enriched tomato juice on liver damage in obese children affected by NAFLDYes: The tomato-supplemented group had a more profound reduction in BMI, HOMA-IR, cholesterol, TG, liver size, and steatosisNo: Leptin decreased in both groups23) Akbulut U, [49] 2021,Turkey1. Age 9–17 years2. BMI z-score > 85th percentile3. Diagnosis of NAFLD4. ALT levels greater than twice the upper limit of the normal level (males > 50 U/L, females > 44 U/L)5. Fatty liver disease detected at ultrasonographyTotal: 45INT: 23CTL: 22INT: Mediterranean diet (composition of 35–40% fat (with < 10% of energy constituting saturated fat),40–44% carbohydrate, and 20% protein)CTL: low-fat diet (composition of 55% of energy from carbohydrates, 20–25% from fat (with < 10% of energy consisting of saturated fat), and 20–25% from protein)Diet3To determine the effects of a Mediterranean Diet or a low-fat diet on reducing hepatic steatosis and insulin resistance in children with NAFLDYes: Over 12 weeks, both Mediterranean and low-fat diets decreased hepatic steatosis and improved insulin sensitivity. The Mediterranean diet group experienced a more significant decrease in insulin resistance24) Cohen CC, [48] 2021,USA1. Adolescent boys aged 11 to 16 years2. Clinical-pathological diagnosis of NAFLDTotal: 39INT: 16CTL: 13INT: low sugar dietCTL: usual dietDiet2To test the effect of longer-term dietary sugar restriction on hepatic de novo lipogenesis (DNL) in adolescent boys with NAFLDYes: Hepatic DNL, hepatic fat, and fasting insulin decreased in the treatment group versus the control group25) Namakin K, [38] 2021,Iran1. Children 12–18 years2. Fatty liver (ultrasonography)3. Vit D level < 30 ng/mLTotal: 101INT: 51;PLB:50INT: Vitamin D capsules, a 50000 U Perl once a weekPLB: placebo with the same dosage, color, and package and for the same durationSupplement3To determine the effect of vitamin D (Vit D) on ultrasonography and laboratory indices of NAFLD and some blood biochemical indicators in childrenYes. The mean changes in hemoglobin (Hb), uric acid, HDL-C, LDL-C, insulin, albumin, and ALT were significantly higher in the study group compared to controls (p < 0.05)No: The mean changes in AST, ALP, and CRP did not significantly differ between the two groups26) Saneian H, [39] 2021,Iran1. Children (5–15 years old) with NAFLD2. Increases liver enzymes more than 40 unit/LTotal: 55INT: 30PLB: 25INT: 50 mg/kg/day L-carnitine twice a dayPLB: identical placebo per daySupplement3To assess the effect of L-carnitine supplementation on NAFLD in children and adolescentsNo: L-carnitine did not have significant effect on improving biochemical andsonographic markers of NAFLD in children and adolescents27) Yurtdas G, [47] 2021,Turkey1. Adolescents (11–18 years)2. BMI ≥ 95th percentile2. With NAFLDTotal: 44INT: 22CTL: 22INT: Mediterranean dietCTL: low-fat dietDiet3To compare the effects of MD versus a standard LFD on hepatic steatosis, liver enzymes, and inflammatory and oxidative stress markers in adolescents with NAFLDYes: At the end of the study, severity of hepatic steatosis, serum transaminase levels, and insulin resistance decreased significantly in both groups with no significant differences between groupsThe amount of decrease in AST levels in the MD group was greater than the LFD group (p < 0.05). In the MD group, serum total antioxidant capacity, paraoxanase-1, and glutathione peroxidase levels increased (p < 0.05); it did not change in the LFD group compared to baseline (p > 0.05). C-Reactive Protein (CRP) levels decreased only in the MD group (p = 0.008), interleukine-6 decreased only in the LFD group (p = 0.031)28) Vos MB, [6] 2022,USA1. Age 8–17 years2) Histologic evidence of NAFLD with or without fibrosis and a NAFLD activity score (NAS) of ≥ 33) ALT ≥ 50 U/lTotal: 67INT: 33PLB: 34INT: losartan capsules (100 mg/day)PLB: placebo capsulesMedication6To determine whether a 24‐week treatment with losartan improves biomarkers of liver inflammation in children with NAFLDNo: Losartan did not significantly reduce ALT, AST, GGT, lipids, glucose, insulin, and HOMA-IR in children with NAFLD compared to placebo29) Schmidt K, [46] 2022,USA1. Latino adolescents (11–18 years)2. Obesity (BMI ≥ 95th percentile)3. Elevated liver fatTotal: 76INT: 42CTL: 34INT: restricting free sugar intake to < 10% of total caloriesCTL: packet of handouts with general diet adviceDiet3The aim of the study was to test the effects of a clinical intervention to reduce dietary sugar compared with standard dietary advice on liver fat change and secondary-endpoint changes in liver fibrosis, liver enzymes, and anthropometricsNo: In Latino youth with obesity, a dietitian-led sugar reduction intervention did not improve liver fat, liver fibrosis, liver enzymes and body composition compared with control30) Rodrigo T, [40] 2022,Sri Lanka1. Children 5–15 years2. BMI > 2 standard deviation for age according to WHO3. AST/ALT ratio < 14. Ultrasound evidence of hepatic steatosis, including grade I to IIITotal: 84INT: 43PLB: 41INT: probiotic capsule (One capsule for children < 12 years and 2 capsules for children > 12 years) + structured diet + physical activityPLB: a capsule without probiotic strains + structured diet + physical activitySupplement6To evaluate the effects of probiotics on metabolic derangement in obese children with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH)No: The probiotics have no advantage over lifestyle modification for improving obesity-associated metabolic derangement in children31) El Amrousy [41], 2022,Egypt1.Obese children less than 18 years2. Biopsy-proven NAFLD3. Serum 25 (OH) D level less than 20 ng/mlTotal: 100INT: 50 PLB: 50INT: vitamin D (2000 IU/day)PLB: shape and packages of the placebo were the same as that of vitamin DSupplement6To evaluate the role of vitamin D supplementation on the hepatic fat content and NAFLD progression in childrenYes: There was a significant improvement of the hepatic steatosis and lobular inflammation by liver biopsy in the treatment group after treatment. There was significant decrease of AST, ALT, TG, LDL, FBG, FBI, and HOMA- IR and significant increase of vitamin D levels and HDL in the treatment group compared to the placebo group (P < 0.05)No: There was no significant effect on the hepatocyte ballooning or hepatic fibrosisAbbreviations : ALT Alanine Aminotransferase, BMI Body Mass Index, DHA Ω-3 Fatty Acid Docosahexaenoic Acid, GGT Gamma-Glutamyl Transferase, HDL High-Density Lipoprotein, INT intervention group, LDL Low-Density Lipoprotein, NAFLD Non-Alcoholic Fatty Liver Disease, PLB placebo group, TG triglycerides, VLDL Very Low-Density Lipoprotein, Vt1 Ventilatory Threshold, VitD Vitamin D, VitE Vitamin E Descriptive analysis of the systematic review 1) Nobili V, [25] 2006, Italy 1. Children (aged 3–18 years) 2. Persistently elevated serum aminotransferase levels 3. Diffusely echogenic liver in imaging studies suggestive of fatty liver 4.No use of drugs known to induce steatosis Total: 90 INT: 45 PLB: 45 INT: vitamin E (600 IU/day) and vitamin C (500 mg/day) + diet PLB: nutritional counseling + placebo Yes: Among subjects who lost excessive weight, ALT and body weight percentage changes were significantly related. HOMA-IR and ALT significantly decreased in both groups No: The addition of antioxidant vitamins E and C to a healthier diet and daily regular physical activity seems to have no significant effect on reducing circulating ALT levels, liver brightness, and IR in NAFLD children 2) Nobili V, [26] 2008, Italy 1. Persistently elevated serum aminotransferase levels 2. Diffusely echogenic liver on imaging studies suggestive of fatty liver 2. Biopsy consistent with the diagnosis of NAFLD Total: 53 INT: 25 PLB: 28 INT: vitamin E (600 IU/day) and vitamin C (500 mg/day) + lifestyle intervention PLB: capsules of placebo + lifestyle intervention Yes: Lifestyle intervention with diet and increased physical activity induces weight loss and significantly improves liver histology and laboratory abnormalities in pediatric NAFLD No: Alpha-tocopherol plus ascorbic acid does not seem to increase the efficacy of lifestyle intervention alone 3) Wang CL, [42] 2008, China 1. Children 10–17 years 2. BMI > 95th percentile for age and sex 3. NASH (ultrasound) 4. ALT > 1.5 times over the upper normal limit Total: 76 INT1: 19 INT2: 19 CTL: 38 INT 1: lifestyle intervention (summer camp) INT 2: vitamin E (100 mg/day) CTL: without any intervention 1. Lifestyle 2. Supplement 4) Akcam M, [22] 2011, Turkey 1. Children 9–17 years 2. Liver steatosis and obesity Total: 67 INT1: 22 INT2: 22 CTL: 23 INT1: metformin (850 mg/day) INT2: Vit E (400 IU/day) CTL: diet, exercise, and behavioral therapy 1. Medication 2. Supplement 5) Lavine J, [23] 2011, United States 1. Patients aged 8 to 17 years with NAFLD (defined by liver biopsy demonstrating > or equal 5% fat content) 2. Persistently elevated levels of ALT were eligible Total: 173 INT1: 58 INT2: 57 PLB: 58 INT1: vitamin E (400 mg/day) INT2: metformin (500 mg/day) PLB: identical placebo 1. Supplement 2. Medication Yes: The mean change in hepatocellular ballooning scores at 96 weeks was significant with vitamin E and metformin compared to placebo No: Neither vitamin E nor metformin was superior to placebo in attaining the primary outcome of sustained reduction in ALT level in patients with pediatric NAFLD 6) Nobili V, [27] 2011 Roma 1. Persistently elevated serum alanine transaminase (ALT ≥ 40 U/l) 2. Diffusely hyperechogenic liver at ultrasonography 3. Liver biopsy consistent with NAFLD Total: 60 INT1: 20 INT2: 20 CTL: 20 INT1: DHA (250 mg/day) INT2: DHA (500 mg/day) CTL: linoleic acid (290 mg/day) supplied with germ oil Yes: DHA supplementation for 6 months reduced liver fat content and increased insulin sensitivity in children with NAFLD. However, 250 mg/day of DHA was as effective as 500 mg/day in obtaining these outcomes No: There was no effect on alanine transaminase and body mass index 7) Nobili V, [28] 2013, Italy 1) Age < 18 years 2) Persistently elevated serum alanine transaminase (ALT 40 U/L) 3) Diffusely hyperechogenic liver at ultrasonography 4) Liver biopsy consistent with NAFLD Total: 60 INT1: 20 INT2: 20 PLB: 20 INT1: DHA (250 mg/day) INT2: DHA (500 mg/day) CTL: linoleic acid (290 mg/day) supplied with germ oil Yes: DHA supplementation improved liver steatosis in children with NAFLD. Doses of 250 mg/day and 500 mg/day of DHA appear equally effective in reducing liver fat content Triglycerides were lower in the DHA groups than in the placebo group at any time, and ALT was lower in these groups from month 12 onwards. HOMA was lower in the DHA 250 mg group vs. placebo at months 6 and 12 8) Ghergherehchi R, [29] 2012, Iran 1. Children with BMI higher than 97th percentile for age and sex 2. ALT, AST levels at least 1.5 times more than the upper limit of normality (5–40 IU/L) 3. Signs of hepatic steatosis in ultrasonography Total: 33 INT: 17 PLB: 16 INT: vitamin E (400 mg/day) + lifestyle PLB: placebo + lifestyle Yes: In 6 months of therapy, there was a significant change in body mass index, serum aminotransferases, triglycerides, total cholesterol, and low-density lipoprotein-cholesterol levels in both groups No. ALT decreased to normal levels in 8 of 17 patients (47.05%) in the lifestyle and vitamin E group and 7 of 16 patients (43.75%) in the lifestyle and placebo group. Similarly, the improvement in the grade of steatosis on ultrasonography after intervention was the same in both groups 9) Jin Rl, [51] 2014, USA 1) Self-identification as Hispanic 2) Ages 11–18 years; BMI ≥ 85th percentile for age and gender 3) Average self-reported consumption of at least 3 servings of sweet beverages (equivalent to 24 fl oz) per day Total: 21 INT: 12 CLT: 9 INT: 3 servings (8 fl oz bottles) of study-provided beverages daily (33 g of glucose per serving) CLT: 3 servings (8 fl oz bottles) of study-provided beverages each day (33 g of fructose per serving) No: there was no significant change in hepatic fat or body weight in either group Yes: In the glucose beverage group there was significantly improved adipose insulin sensitivity, high sensitivity C-reactive protein (hs-CRP), and low-density lipoprotein (LDL) oxidation 10) Alisi A, [30] 2014, Italy 1.BMI > 85th percentile 2. Biopsy-proven NAFLD Total: 44 INT: 22 PLB: 22 INT: VSL#3 (sachets) + lifestyle intervention PLB: placebo sachets + lifestyle intervention Yes: Supplementation with VSL#3 significantly improves fatty liver and BMI in children with NAFLD No: No between-group differences were detected in triglycerides, HOMA and ALT 11) Janczyk W, [31] 2015, Poland 1. Age > 5 < 19 years 2. Overweight or obesity 3. ALT activity ≥ 1.3 times the upper limit of normal 4. Presence of hyperechogenic liver on ultrasound or 5. Liver histology consistent with NAFLD/nonalcoholic steatohepatitis Total: 64 INT: 30 PLB: 34 INT: omega-3 fatty acids, DHA and EPA (450–1300 mg/day) PLB: omega-6 sunflower oil Yes: Patients in the omega-3 group had lower levels of aspartate aminotransferase and gamma-glutamyl transpeptidase, and significantly higher levels of adiponectin No: Omega-3 fatty acid supplementation did not increase the number of patients with decreased ALT levels, and it did not affect liver steatosis on ultrasound 12) Miccheli A, [32] 2015, Italy 1. BMI > 85th percentile 2. Biopsy-proven NAFLD Total: 44 INT: 22 PLB:22 INT: VSL#3 (1 sachet/day if the subject’s age was < 10 years, 2 sachets/day in children aged ≥ 10 years) PLB: placebo (1 sachet/day if the subject’s age was < 10 years, 2 sachets/day in children aged ≥ 10 years) 13) Pacifico L, [33] 2015, Italy 1. Age < 18 years 2. BMI > 85th percentile according to age- and gender 3. Persistently elevated ALT levels 4. NAFLD diagnosis by MRI and liver biopsy consistent with NAFLD Total: 51 INT. 25 PLB: 26 INT: DHA (250 mg/day) PLB: linoleic acid (290 mg/day) Yes: DHA supplementation decreases liver and visceral fat and ameliorates metabolic abnormalities (ALT, triglycerides, BMI, insulin sensitivity) in children with NAFLD No: There were no significant between-group changes for LV function 14) Della Corte C, [34] 2016, Italy 1. Age 4–16 years 2. Liver biopsy result consistent with a diagnosis of NAFLD/NASH 3. Decreased serum vitamin D levels (< 20 ng/ml) 4. ALT levels < 10 upper limit of normal 5. No laboratory and/or clinical signs of liver decompensation Total: 41 INT:18 PLB:23 INT: DHA (500 mg/day) + vitamin D (800 IU/day) PLB: identical capsules (placebo) Yes: DHA plus vitamin D treatment reduced the NAFLD Activity Score (NAS), in the treatment group (5.4 v1.92; p < 0.001 for baseline versus end of study). The triglycerides (174.5 vs. 102.15 mg/dl), ALT (40.25 vs. 24.5 UI/l) and HOMA-IR (4.59 vs. 3.42) were all decreased with treatment No: There was no change in fibrosis score 15) Famouri F, [35] 2017, Iran Total: 40 INT:20 PLB: 20 INT: silymarin tablets (5 mg/kg/d, divided 3 doses with meal) + lifestyle PLB: lifestyle Yes: Silymarin can improve fatty infiltration of liver and liver function in children and adolescents. ALT, AST, and TG were improved significantly No: LDL and HDL did not change during intervention in case group 16) Famouri F, [36] 2017, Iran 1. Children 10–18 years 2. BMI ≥ 85th percentile 3. Sonographic findings of NAFLD Total: 64 INT: 32 PLB: 32 INT: Prokid -Lactobacillus and Bifidobacterium (1 capsule/day) CTL: placebo capsule Yes: Supplementation with probiotic can be effective in improving pediatric NAFL. ALT, AST, cholesterol, HDL, TG, and waist circumference decreased After the trial, compared with the placebo group, the frequency of normal liver ultrasonography was significantly higher, and the frequency of high-grade fatty liver was significantly lower than the placebo group (p < 0.05) 17) De Lira CT, [44] 2017, Brazil 1. Age 13–18 years with good general health 2. BMI > 95th percentile according to the Centers for Disease Control (CDC) 3. Tanner stage 3 to 4 Total: 84 INT1: 26 INT2: 25 CTL: 33 INT1: high-intensity training (HIT) + nutritional, psychological and clinical counseling. INT2: low-intensity training (LIT) + nutritional, psychological and clinical counseling CTL: adolescents with lower intrinsic motivation 18) Schwimmer JB, [50] 2018, USA 1. Adolescent boys aged 11 to 16 years 2. Clinical-pathological diagnosis of NAFLD and current evidence of active disease Total: 40 INT: 20 CTL: 20 INT: low sugar diet CTL: usual diet Yes: Significant improvement in hepatic steatosis. ALT and total cholesterol levels improved No: There were no changes in glucose, insulin, and insulin resistance 19) Chan DFY [45], 2018, Hong Kong 1. Post-pubertal adolescents aged 14-–8 years 2. Primary obesity (BMI ≥ Pc 95th of a local reference) Total: 52 INT: 26 [20] CTL: 26 [22] INT phase I (INT PI): dietitian-led lifestyle modification intervention (D-MLP) Maintenancephase II (INT MPII): bimonthly visits for dietary advice (P-CON) CTL: usual clinical routine pediatric consultations 20) Nobili V, [37] 2019, Italy 1. Children 4–16 years with liver steatosis (with biopsy) 2. ALT levels < 10 upper limit of normal 3. Without signs of liver decompensation Total: 70 INT: 35 PLB: 35 INT: hydroxytyrosol (HXT) (oral dose of 7.5 mg + 10 mg of vitamin E) PLB: capsules of placebo Yes: The treatment improved the main oxidative stress parameters (carbonylated proteins (PCOs), S-nitrosylated proteins (PSNOs) and advanced glycation end products (AGEs)), insulin resistance (TG, fasting insulin and HOMA-IR), and steatosis in children with NAFLD No: Anthropometric parameters remained almost unchanged in both groups (Placebo and Treatment arms) 21) Goyal P, [24] 2019, India Total: 106 INT1:26 INT2:27 INT3:26 PLB:27 INT1: probiotics capsules VSL#3 + Lifestyle INT2: probiotics capsules VSL#3 INT3: lifestyle PLB: placebo capsules (corn flour) Supplement + Lifestyle 22) Negri R, [43] 2020, Italy 1.Children 4–14 years 2. BMI > 85th percentile 2. Liver steatosis by US Total: 52 (T1) INT 34; PLB 27 (T2) INT 26; PLB 26 Cross-over trial design INT: calorie-restricted regimen (CRC) + lycopene-enriched tomato juice supplementation together with basil and oregano extract in extra virgin olive oil PLB: calorie-restricted regimen Yes: The tomato-supplemented group had a more profound reduction in BMI, HOMA-IR, cholesterol, TG, liver size, and steatosis No: Leptin decreased in both groups 23) Akbulut U, [49] 2021, Turkey 1. Age 9–17 years 2. BMI z-score > 85th percentile 3. Diagnosis of NAFLD 4. ALT levels greater than twice the upper limit of the normal level (males > 50 U/L, females > 44 U/L) 5. Fatty liver disease detected at ultrasonography Total: 45 INT: 23 CTL: 22 INT: Mediterranean diet (composition of 35–40% fat (with < 10% of energy constituting saturated fat),40–44% carbohydrate, and 20% protein) CTL: low-fat diet (composition of 55% of energy from carbohydrates, 20–25% from fat (with < 10% of energy consisting of saturated fat), and 20–25% from protein) 24) Cohen CC, [48] 2021, USA 1. Adolescent boys aged 11 to 16 years 2. Clinical-pathological diagnosis of NAFLD Total: 39 INT: 16 CTL: 13 INT: low sugar diet CTL: usual diet 25) Namakin K, [38] 2021, Iran 1. Children 12–18 years 2. Fatty liver (ultrasonography) 3. Vit D level < 30 ng/mL Total: 101 INT: 51; PLB:50 INT: Vitamin D capsules, a 50000 U Perl once a week PLB: placebo with the same dosage, color, and package and for the same duration Yes. The mean changes in hemoglobin (Hb), uric acid, HDL-C, LDL-C, insulin, albumin, and ALT were significantly higher in the study group compared to controls (p < 0.05) No: The mean changes in AST, ALP, and CRP did not significantly differ between the two groups 26) Saneian H, [39] 2021, Iran 1. Children (5–15 years old) with NAFLD 2. Increases liver enzymes more than 40 unit/L Total: 55 INT: 30 PLB: 25 INT: 50 mg/kg/day L-carnitine twice a day PLB: identical placebo per day No: L-carnitine did not have significant effect on improving biochemical and sonographic markers of NAFLD in children and adolescents 27) Yurtdas G, [47] 2021, Turkey 1. Adolescents (11–18 years) 2. BMI ≥ 95th percentile 2. With NAFLD Total: 44 INT: 22 CTL: 22 INT: Mediterranean diet CTL: low-fat diet Yes: At the end of the study, severity of hepatic steatosis, serum transaminase levels, and insulin resistance decreased significantly in both groups with no significant differences between groups The amount of decrease in AST levels in the MD group was greater than the LFD group (p < 0.05). In the MD group, serum total antioxidant capacity, paraoxanase-1, and glutathione peroxidase levels increased (p < 0.05); it did not change in the LFD group compared to baseline (p > 0.05). C-Reactive Protein (CRP) levels decreased only in the MD group (p = 0.008), interleukine-6 decreased only in the LFD group (p = 0.031) 28) Vos MB, [6] 2022, USA 1. Age 8–17 years 2) Histologic evidence of NAFLD with or without fibrosis and a NAFLD activity score (NAS) of ≥ 3 3) ALT ≥ 50 U/l Total: 67 INT: 33 PLB: 34 INT: losartan capsules (100 mg/day) PLB: placebo capsules 29) Schmidt K, [46] 2022, USA 1. Latino adolescents (11–18 years) 2. Obesity (BMI ≥ 95th percentile) 3. Elevated liver fat Total: 76 INT: 42 CTL: 34 INT: restricting free sugar intake to < 10% of total calories CTL: packet of handouts with general diet advice 30) Rodrigo T, [40] 2022, Sri Lanka 1. Children 5–15 years 2. BMI > 2 standard deviation for age according to WHO 3. AST/ALT ratio < 1 4. Ultrasound evidence of hepatic steatosis, including grade I to III Total: 84 INT: 43 PLB: 41 INT: probiotic capsule (One capsule for children < 12 years and 2 capsules for children > 12 years) + structured diet + physical activity PLB: a capsule without probiotic strains + structured diet + physical activity 31) El Amrousy [41], 2022, Egypt 1.Obese children less than 18 years 2. Biopsy-proven NAFLD 3. Serum 25 (OH) D level less than 20 ng/ml Total: 100 INT: 50 PLB: 50 INT: vitamin D (2000 IU/day) PLB: shape and packages of the placebo were the same as that of vitamin D Yes: There was a significant improvement of the hepatic steatosis and lobular inflammation by liver biopsy in the treatment group after treatment. There was significant decrease of AST, ALT, TG, LDL, FBG, FBI, and HOMA- IR and significant increase of vitamin D levels and HDL in the treatment group compared to the placebo group (P < 0.05) No: There was no significant effect on the hepatocyte ballooning or hepatic fibrosis Abbreviations : ALT Alanine Aminotransferase, BMI Body Mass Index, DHA Ω-3 Fatty Acid Docosahexaenoic Acid, GGT Gamma-Glutamyl Transferase, HDL High-Density Lipoprotein, INT intervention group, LDL Low-Density Lipoprotein, NAFLD Non-Alcoholic Fatty Liver Disease, PLB placebo group, TG triglycerides, VLDL Very Low-Density Lipoprotein, Vt1 Ventilatory Threshold, VitD Vitamin D, VitE Vitamin E The studies were insufficient to synthesize sex distribution. No studies were found that evaluate the effect of traditional medicine or surgical treatments on MASLD parameters. Twenty-four studies that met the inclusion criteria (Jadad score > 3) were included in the meta-analysis. However, one of these studies [27] did not provide the necessary data (means and standard deviations) for the analysis, so its data were not included in the final findings. The following outcomes describe the significant size of effects. Overall point effects estimations > 0.20 (i.e., ALT, AST, BMI, and HOMA-IR) were adjusted by baseline values and for a small sample size with Hedges' g. Liver enzymes (primary outcome) Liver enzyme levels, ALT, and AST (unadjusted in Figs. 3A and 4A) demonstrated responsiveness to interventions. ALT levels were significantly reduced (Cohen's d = − 0.34), primarily influenced by diet, lifestyle, and supplements. AST levels exhibited a noteworthy overall reduction (Cohen's d = − 0.52), driven by lifestyle changes (Cohen's d = − 0.35) and substantial impact from supplements (Cohen's d = − 0.81), while medication showed a modest effect (Cohen's d = − 0.17). The adjustment with Hedge’s g had smaller 95% confidence intervals, as shown in Figs. 3B and 4B. Forest plot of ALT levels using random effects model. Panel A shows the treatment’s overall effect was small to medium (Cohen-d − 0.34 95%CI − 0.65, − 0.03). Most studies showed the effect on improving the ALT concentration. Panel B shows the overall adjusted size of the effect remained the same with smaller 95% confidence intervals Forest plot of AST levels using random effects model. Panel A shows medium effect on AST. Panel B shows less uncertainty with smaller confidence intervals Cardiometabolic risk variables (associated outcomes) In general, the analyses found notable effects on cardiometabolic risk variables. The BMI forest plot (Fig. 5A) shows significant modification through dietary interventions Cohen's d = − 0.53 and supplements, particularly vitamin E in combination with lifestyle changes and other strategies (Cohen's d = − 0.37). The overall effect across all treatments was − 0.27, indicating a trend toward significance despite considerable heterogeneity (I2 = 89.8%). The adjustment with Hedge’s g had smaller 95% confidence intervals for BMI, as shown in Fig. 5B. Waist circumference (Additional file 1: Supplemental Fig. 1) was also positively impacted by dietary changes Cohen's d = − 0.51 and lifestyle modifications Cohen's d = − 0.25, with an overall modest effect of − 0.1 and moderate heterogeneity (I2 = 28.6%). Other cardiometabolic risk factors were insulin resistance and lipid concentration. Forest plot of BMI using random effects model. Panel A shows the overall effect on BMI was small (Cohen-d = − 0.27 (95%CI − 0.55, 0.01) p = 0.06. Michelli, et al. [32] has the highest size of effect, more than 3 standard deviations of difference. This big difference was attributed to differences in the opposite effects of placebo vs. active treatment. Panel B showed adjusted values diminishing the variation of Michelli study and increasing precision in the 95% confidence interval Insulin resistance Insulin resistance, assessed by HOMA-IR, showed an overall reduction in Cohen’s d = − 0.30, predominantly influenced by supplements Cohen’s d = − 0.64 (Fig. 6A, with adjustment in Fig. 6B). Forest plot of HOMA-IR calculation using random effects model. Panel A shows treatments had small to medium effect on HOMA-IR levels. Panel B shows increased precision with adjusted size of effects with smaller 95% confidence intervals No significant effects No significant effects were observed for GGT, glucose, total cholesterol, LDL-c, and triglycerides (Additional files 2, 3, 4, 5, 6: Supplemental Figs. 2, 3, 4, 5, and 6), except for a modest reduction in glucose with supplements Cohen’s d = − 0.30 (95%CI: − 0.59, − 0.01). The combination of supplements and lifestyle exhibited a negligible effect, potentially attributed to heterogeneity. Heterogeneity sources A meta-regression analysis was conducted to detect possible explanations for heterogeneity. We included mean age, mean BMI, study duration, and GDP from each country. The main results are described in Table 3. The heterogeneity of studies was explained partially with small effects by age, BMI, GDP, and study duration. Meanwhile, the size of effect due to changes in BMI had medium effects on the concentration of ALT and AST (Additional files 7, 8: Supplemental Figs. 7 and 8). An interesting finding was the effect of age on HOMA-IR response; younger children showed better responses (Additional file 9: Supplemental Fig. 9). Table 3Meta-regression coefficientsVariables (z-transf)BMIAgeGIPDurationConstantd-Cohen BMI†Egger p-valueBMI-—-0.181 (− 0.169, 0.531) − 0.107 (− 0.487, 0.606)0.246 (− 0.114, 0.606) − 0.28 (− 0.59, 0.03)-—-0.003ALT0.014 (− 0.292, 0.319)0.219 (− 0.101, 0.538) − 0.325 (− 0.643, − 0.01)**0.311 (0.024, − 0.598)** − 0.31 (− 0.57, − 0.05)0.698 (0.189, 1.206)***0.018AST0.128 (− 0.324, 0.581)0.28 (− 0.215, 0.775) − 0.151 (− 0.70, 0.398)0.28 (− 0.201, 0.761) − 0.58 (− 0.97, − 0.18)0.973 (0.617, 1.329)*** < 0.001LDL-c − 0.384 (− 0.704, − 0.063)** − 0.018 (− 0.355, 0.318)0.489 (0.103, 0.874)** − 0.178 (− 0.573, 0.218) − 0.31 (− 0.57, − 0.05) − 0.456 (− 0.954, 0.042)*0.018GGT − 0.517 (− 1.232, 0.199)1.071 (− 0.057, 2.20) − 0.31 (− 1.44, 0.82)0.006 (− 0.677, 0.689) − 0.101 (− 0.52, 0.31)0.144 (− 0.481, 0.769)0.676Glucose0.028 (− 0.496, 0.552)0.211 (− 0.358, 0.779)0.458 (− 0.013, 0.928) − 0.505 (− 0.885, − 0.124)0.05 (− 0.26, 0.36)0.037 (− 0.434, 0.509)0.084HOMA-IR − 0.285 (− 0.59, 0.02)*0.576 (0.228, 0.924)**0.254 (− 0.007, 0.515) − 0.175 (− 0.394, 0.044) − 0.174 (− 0.35, − 0.004)0.449 (− 0.135, 1.035)0.045TC0.065 (− 0.285, 0.415)0.127 (− 0.235, 0.489)0.232 (− 0.174, 0.639) − 0.102 (− 0.481, 0.276) − 0.16 (− 0.47, 0.15)0.106 (− 0.215, 0.427)0.476TG − 0.06 (− 0.348, 0.227) − 0.028 (− 0.318, 0.262)0.445 (0.087, 0.803)** − 0.158 (− 0.446, 0.13) − 0.20 (− 0.46, 0.06) − 0.10 (− 0.528, 0.328)0.223WC − 0.115 (− 0.470, 0.239) − 0.054 (− 0.334, 0.227)0.121 (− 0.237, 0.480)0.18 (− 0.020, 0.379) − 0.14 (− 0.30, 0.02)0.472 (− 0.081, 1.025)*0.003Egger: small studies effect. †Meta regression of z-transformed variables on individual BMI’s Cohen-d size of effectAbbreviations: GBMI body mass index, DP gross domestic product, TG Triglycerides, TC total cholesterol, LDL Low density lipoprotein, WC Waist circumference*p-value < 0.1, **p < 0.05, ***p < 0.001 Meta-regression coefficients Egger: small studies effect. †Meta regression of z-transformed variables on individual BMI’s Cohen-d size of effect Abbreviations: GBMI body mass index, DP gross domestic product, TG Triglycerides, TC total cholesterol, LDL Low density lipoprotein, WC Waist circumference *p-value < 0.1, **p < 0.05, ***p < 0.001 The Egger analysis showed that small sample sizes of the studies were significant contributors to bias. Most studies had small sample sizes with wide effects, contributing to heterogeneity (Additional file 10: Supplemental Fig. 10). The sensitivity analysis showed that the overall effect size remained relatively stable across the different studies, indicating that no study unduly influenced meta-analysis results. The results of the sensitivity analysis are described in the (Additional file 14) Supplementary File 14 . Bibliometric analysis The bibliometric analysis was conducted using data from 29 publications in the systematic review (Additional file 11: Supplemental Fig. 11, panel A). These publications received 1834 citations, excluding instances where the authors cited their own work. On average, each publication received approximately 95.9 citations. The h-index, which tells us about the impact of the research, was 19. Table 4 shows the ten most highly cited publications from the network analysis of MASLD and obesity in children. Table 4Top 10 highly cited publications on the network analysis of MASLD and obesity in pediatric populationRankAuthor names (year)InstitutionCountryLanguageJ Impact Factor (2022)Total citations(by Dec 2023)Reference (PMID) 1Lavine, JE et al. (2011)Columbia UniversityUSAEnglish120.7761 [23] (21521847)2Nobili, V et al. (2008)Bambino Gesu Children's Hosp & Res InstItalyEnglish14303 [26] (18537181)3Alisi, A et al. (2014)Bambino Gesu Children's Hosp & Res InstItalyEnglish7.6302 [30] (24738701)4Nobili, V et al. (2011)Bambino Gesu Children's Hosp & Res InstItalyEnglish5.2207 [27] (21233083)5Famouri, F et al. (2017)Isfahan Univ Med SciIranEnglish2.9154 [36] (28230607)6Nobili, V et al. (2006)Bambino Gesu Children's Hosp & Res InstItalyEnglish7.6132 [25] (17206944)7Schwimmer, JB et al. (2019)Emory UniversityUSAEnglish120.7131 [50] (30667502)8Nobili, V et al. (2013)Bambino Gesu Children's Hosp & Res InstItalyEnglish3.9109 [28] (23220074)9Wang, CL et al. (2008)Zhejiang UniversityChinaEnglish4.396 [42] (18330955)10Janczyk, W et al. (2015)Children's Memorial Health InstitutePolandEnglish5.189 [31] (25771388) Top 10 highly cited publications on the network analysis of MASLD and obesity in pediatric population Co-authorship analysis (Additional file 11) Supplemental Figure 11, panel A, shows the co-authorship map, displaying 246 authors, with 27 having at least two published papers. Few authors (n = 3) had the highest influence based on total link strength (12 documents, 1340 citations, 182 total link strength). The research group led by Lavine Joel E appears to be the oldest in publications in the field of MASLD and obesity in the pediatric population. In terms of total link strength, Emory University had the most influence (5 documents, 553 citations, 13 total link strength), followed by the University of California, San Diego (4 documents, 902 citations, 13 total link strength) and Columbia University (2 documents, 767 citations, 9 total link strength) (Additional file 11) Supplemental Figure 11, Panel B). The co-authorship map reflected nine countries, five of which met the threshold of having at least two papers published for co-authorship. (Additional file 11) Supplemental Figure 11, panel C shows the number of papers provided by country, with Italy having the highest influence (11 documents, 1329 citations, 2 total link strength) and the longest track record of producing publications in the field of MASLD and obesity in the pediatric population. The USA (9 documents, 1627 citations, 2 total link strength) and Iran (3 documents, 163 citations, 0 total link strength) followed. Discussion This meta-analysis evaluated the effectiveness of supplementation, diet, lifestyle, and medication interventions in improving biochemical and anthropometric parameters in children with MASLD. Our results showed a significant but small effect size on ALT and AST levels, primarily influenced by supplementation, diet, and lifestyle modifications. Diet and supplemental interventions resulted in a slight decrease in BMI. ALT is commonly used as a screening test for MASLD in children, and when combined with a high AST level, it indicates more severe liver damage [52]. Therefore, the observed decrease in these enzyme levels could indicate an improvement in liver damage in children driven by supplement interventions, particularly with vitamin D and probiotics [32, 41]. Only two studies in this review demonstrated a decrease in liver steatosis, ALT, and AST after interventions with vitamin D [41] and probiotics [32]. A similar result was observed in one study reporting a decrease in ALT (but not in AST) with DHA [33]. The benefits of these supplements, alongside DHA, are discussed in the context of their mechanisms and potential in managing MASLD [53]. Vitamin D supplementation in MASLD improves insulin sensitivity by regulating insulin gene transcription and improving glucose intake by muscle and reduces hepatic and adipose tissue inflammation. Higher vitamin D levels are correlated with higher adiponectin levels, while vitamin D deficiency activates inflammation processes that increase liver inflammation. Additionally, vitamin D diminishes liver fibrosis; for instance, in vitro, vitamin D inhibits the proliferation of liver stellate cells [53]. Low levels of vitamin D have been observed in the pediatric population with MASLD [54]. Regarding probiotics, there are no precise mechanisms behind their positive effect on liver transaminases and steatosis. However, studies in both children and adults have observed benefits in liver parameters [54]. In terms of DHA supplementation, omega − 3 polyunsaturated fatty acids (PUFAs) regulate mechanisms related to fat accumulation in the liver, such as de novo lipogenesis, fatty acid oxidation, triglyceride catabolism, and have anti-inflammatory effects [55]. Considering that oxidative stress plays an important role in MASLD progression, the effect of vitamin E on MASLD parameters has been evaluated due to its antioxidant activity. Additionally, vitamin E regulates the expression of genes encoding for interleukin IL-1b, IL-2, and IL-4 (El Hadi H, PMID: 29,337,849). In adults, vitamin E has improved ALT and AST levels [56], contrasting with no beneficial effects in pediatric patients [22, 23]. The results indicated that vitamin D, DHA, and probiotics can improve liver enzyme levels in children with MASLD. However, there is not enough evidence to recommend their use in clinical settings for managing MASLD in children. The supplement doses and study sample sizes varied widely across the evaluated studies. Hence, future research should aim to evaluate the recommended dosage as part of MASLD treatment in children. Furthermore, it is essential to highlight that most studies evaluating supplement interventions also offered lifestyle recommendations to both intervention and control groups. As a result, the observed effects could be a response to the interaction between supplements and lifestyle modifications in children. Diet and exercise (lifestyle modifications) are the first treatment options for MASLD in children to reduce risk factors associated with this condition [52]. Our results showed that the Mediterranean diet [47] and reduction of dietary sugar [46] interventions had a positive pooled effect on BMI, WC, ALT, AST, GGT, and HOMA-IR [46, 47]. However, the effect size was small, and both studies were at high risk of bias. Despite the randomization process, the BMI of participants in the intervention and control groups differed at baseline. This discrepancy affected the meta-analysis results, even after adjusting for BMI baseline. Therefore, these results should be carefully interpreted. Other studies have shown Mediterranean diet has efficacy in reducing BMI, body fat content, and abdominal obesity in children and adolescents [57]. Still, few studies have evaluated its effects on MASLD. Otherwise, lifestyle interventions had a significant pooled effect on decreasing hepatic enzymes and LDL-C but not in anthropometric variables. There is no evidence to suggest a specific diet for managing pediatric MASLD. Current guidelines advise avoiding sugar-sweetened beverages, improving diet quality, increasing physical activity, and reducing screen time [52]. Our results suggest that a combination of lifestyle modifications and supplementation may be more effective than lifestyle modifications alone in improving MASLD in children. However, more RCTs are needed to determine the most effective doses of supplements, the best combinations of these, and lifestyle changes, depending on the pediatric population to be treated. A limited number of studies have evaluated the effects of medications on children. The present meta-analysis did not show an overall improvement in any of the parameters being assessed of MASLD due to medication intervention with metformin and losartan. One of the included studies found that metformin improves hepatocellular ballooning [19], but its effect was like that of vitamin E supplementation. Although biochemical parameters did not show a significant reduction, vitamin E supplementation and metformin could have significant and measurable effects on MASLD. Further investigation is needed to determine whether treatment or supplementation provides a more significant benefit. Due to the lack of evidence, there are no current recommendations for medication treatment in pediatric MASLD. A recent retrospective case series study [58] evaluated the effect of a GLP-1 receptor agonist on ALT concentrations in nine children with type 2 diabetes mellitus and elevated ALT levels. The study found a 69% reduction in ALT levels, suggesting a potential beneficial effect of this drug on MASLD management that should be addressed in RCTs. GLP-1 receptor agonists have shown improvement in steatosis and steatohepatitis in adults with type 2 diabetes [59]. Additionally, pioglitazone has shown promise in ameliorating steatosis and lobular inflammation in adults with NASH [60]. However, the use of pioglitazone in the pediatric population is not approved due to concerns regarding cardiovascular risks and bladder cancer [61]. Clinical trials are underway to test novel drugs like GLP-1 receptor agonists and PPAR-γ agonists such as lanifibranor [62]. However, none of these trials involve children. Our research highlights a lack of high-quality evidence to form specific therapeutic recommendations for MASLD in children concerning supplementation, diet, lifestyle, and medication. We aimed to reduce bias by adjusting for baseline BMI, which improved precision, but heterogeneity remained high, and effect sizes were small. The stratified meta-analysis by intervention category to account for the age differences by intervention types allowed the assessment of effect sizes considering age-related variability. We utilized meta-regression for potential sources of heterogeneity, employing age as a moderator variable to assess its impact on intervention outcomes. The combination of stratified meta-analysis and meta-regression facilitated a detailed interpretation of the findings, enabling the assessment of the influence of age differences on the efficacy of the studied interventions. The absence of RCTs might be due to ethical considerations when involving children [63]. Ethical guidelines require minimizing risks and ensuring that interventions are non-invasive and effective. Informed consent presents another challenge, involving evaluating children’s capacity to comprehend the study’s implications. Parental consent is typically necessary, but researchers must communicate study details in an age-appropriate manner and ensure voluntary participation [64]. The bibliometric analysis shows that there is an increasing focus on research related to MASLD and pediatric obesity. This indicates that there are collaborative relationships among a small number of researchers and organizations dedicated to developing treatments [65, 66]. Despite these collaborations, the analysis reveals a significant gap in research across various countries, limiting the understanding of cultural and environmental influences on MASLD development. Given the findings of our recent study [67] on the substantial impact of environmental disparities on adult stature and metabolic outcomes, future research should prioritize exploring these environmental and cultural factors in diverse populations. Our study acknowledges several limitations, including the scarcity of researchers focusing on MASLD in the pediatric population and the lack of RCTs in certain regions, indicating a concentration of research efforts in a few geographical areas. We also detected publication bias, where studies with small sample sizes and positive results may disproportionately influence overall outcomes. It is essential to critically evaluate whether the influence of highly cited small-sample studies is justified or biased. We recognize high heterogeneity among included studies. Meta-regressions identified baseline BMI as a significant source of heterogeneity, suggesting that differences in baseline weight substantially affect the effectiveness of therapeutic interventions on liver enzyme levels. To address this, we performed meta-regressions, which significantly reduced variations within studies, as indicated by lower tau2 values. However, the high I2 values showed that the relative percentage of variation due to heterogeneity remained considerable. Our bibliometric analysis suggests future research should include underrepresented regions to provide a more comprehensive global perspective on MASLD, contributing to effective and tailored treatment strategies. Conclusion In conclusion, the effective management of MASLD in children requires a multifaceted approach. Lifestyle changes (diet and physical activity) continue to be the first option for treating MASLD. While diet, supplements, and lifestyle adjustments have shown significant effects, the clinical impact size was minimal when considering baseline BMI. Therefore, more high-quality studies are needed to offer therapeutic recommendations. Our findings call for increased research efforts to develop evidence-based therapeutic strategies, aiming to improve the natural course of MASLD progression and reduce the risk of advanced liver disease from an early age. Supplementary Information Additional file 1: Supplemental Fig. 1. Forest plot of waist circumference measurement using random effects model. Comment: The effect of treatment on waist circumference was small. Additional file 2: Supplemental Fig. 2. Forest plot of GGT levels using random effects model. Comment: No effect of treatments on GGT. Additional file 3: Supplemental Fig. 3. Forest plot of glucose levels using random effects model. Comment: Glucose. Treatments did not show the effect on glucose levels. Additional file 4: Supplemental Fig. 4. Forest plot of Total Cholesterol levels using random effects model. Comment: Treatments showed an effect of -0.14 (-0.40, 0.11) on Total Cholesterol levels. Additional file 5: Supplemental Fig. 5. Forest plot of LDL-c levels using random effects model. Comment: Treatments showed an effect of 0.34 (0.03, 0.65) on LDL-c levels. Additional file 6: Supplemental Fig. 6. Forest plot of triglycerides level. Coefficients were computed with a random effects model. Comment: The treatment effect size on triglyceride concentration was small. Additional file 7: Supplemental Fig. 7. Meta-regression of ALT concentration on the standardized effect of BMI. The determination coefficient was (R2) of 33.4, but when Michele's extreme value was eliminated, the R2 dropped to 2.5%. The figure does not include the outlier. Additional file 8: Supplemental Fig. 8. Meta-regression of the standardized effect size of BMI to explain AST concentration. The R2 was 80%; when an outlier was eliminated, the R2 dropped to 36%. The figure does not include the outlier. Additional file 9: Supplemental Fig. 9. Meta-regression of HOMA-IR on age. The R2 was 70%. The standardized effect of age was 0.57 (95%CI: 0.23, 0.92) adjusted by the duration of intervention, gross internal product, and BMI. Additional file 10: Supplemental Fig. 10. Funnel plots of random effects models for BMI, HOMA-IR, AST, and ALT. The Egger analysis showed significant effects from small sample size studies. Additional File 11: Supplemental Figure 11. Co-authorship analysis. (A) Graphical overlay visualization of author contribution by link strength. (B) Graphical overlay visualization of organization contribution by link strength. (C) Graphical overlay visualization of countries' contribution by link strength. Clustering was performed using VOSviewer 1.6.19. The color indicates the average published year. The thickness of the lines indicates the strength of the relationship. Additional File 12. Additional File 13. Additional File 14. Acknowledgements We thank the Population Health & Biostatistics Division at UTRGV, the Universidad México Americana del Norte, and Silanes Laboratory for supporting the paper's publication. Abbreviations Alanine aminotransferase Aspartate aminotransferase Body mass index Ω-3 Fatty acid docosahexaenoic acid Gross domestic product Gamma-glutamyl transferase High-density lipoprotein Homeostatic model assessment for insulin resistance Intervention group Low-density lipoprotein Metabolic dysfunction-associated steatotic liver disease Non-alcoholic fatty liver disease Non-alcoholic steatohepatitis Placebo group Randomized clinical trials Random-effects meta-analysis Total cholesterol Triglycerides Very low-density lipoprotein Ventilatory threshold Vitamin D Vitamin E Waist circumference Authors' contributions All authors participated in this paper’s design, data analysis, and writing. All authors read and approved the final manuscript. Data Availability Additional File 12 contains the extracted data used in the meta-analysis. Additional File 13 describes and illustratesthe data search strategies. Declarations Ethics approval and consent to participate This meta-analysis did not involve any direct interaction with human or animal subjects; it exclusively utilized publicly available data from previously published studies. Consequently, there was no requirement for Institutional Review Board (IRB) approval. The protocol was registered in PROSPERO (CRD42023393952) to ensure methodological transparency and to adhere to best practices in systematic review research. Competing interests The authors declare that they have no competing interests. They do not work for private laboratories and have not received any payments. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Additional file 1: Supplemental Fig. 1. Forest plot of waist circumference measurement using random effects model. Comment: The effect of treatment on waist circumference was small. Additional file 2: Supplemental Fig. 2. Forest plot of GGT levels using random effects model. Comment: No effect of treatments on GGT. Additional file 3: Supplemental Fig. 3. Forest plot of glucose levels using random effects model. Comment: Glucose. Treatments did not show the effect on glucose levels. Additional file 4: Supplemental Fig. 4. Forest plot of Total Cholesterol levels using random effects model. Comment: Treatments showed an effect of -0.14 (-0.40, 0.11) on Total Cholesterol levels. Additional file 5: Supplemental Fig. 5. Forest plot of LDL-c levels using random effects model. Comment: Treatments showed an effect of 0.34 (0.03, 0.65) on LDL-c levels. Additional file 6: Supplemental Fig. 6. Forest plot of triglycerides level. Coefficients were computed with a random effects model. Comment: The treatment effect size on triglyceride concentration was small. Additional file 7: Supplemental Fig. 7. Meta-regression of ALT concentration on the standardized effect of BMI. The determination coefficient was (R2) of 33.4, but when Michele's extreme value was eliminated, the R2 dropped to 2.5%. The figure does not include the outlier. Additional file 8: Supplemental Fig. 8. Meta-regression of the standardized effect size of BMI to explain AST concentration. The R2 was 80%; when an outlier was eliminated, the R2 dropped to 36%. The figure does not include the outlier. Additional file 9: Supplemental Fig. 9. Meta-regression of HOMA-IR on age. The R2 was 70%. The standardized effect of age was 0.57 (95%CI: 0.23, 0.92) adjusted by the duration of intervention, gross internal product, and BMI. Additional file 10: Supplemental Fig. 10. Funnel plots of random effects models for BMI, HOMA-IR, AST, and ALT. The Egger analysis showed significant effects from small sample size studies. Additional File 11: Supplemental Figure 11. Co-authorship analysis. (A) Graphical overlay visualization of author contribution by link strength. (B) Graphical overlay visualization of organization contribution by link strength. (C) Graphical overlay visualization of countries' contribution by link strength. Clustering was performed using VOSviewer 1.6.19. The color indicates the average published year. The thickness of the lines indicates the strength of the relationship. Additional File 12. Additional File 13. Additional File 14. Data Availability Statement Additional File 12 contains the extracted data used in the meta-analysis. Additional File 13 describes and illustratesthe data search strategies.